Quest Laboratories Ltd
Incorporated in 1998, Quest Laboratories Ltd is a pharmaceutical manufacturer specializing in diverse therapeutic segments[1]
- Market Cap ₹ 167 Cr.
- Current Price ₹ 102
- High / Low ₹ 153 / 80.0
- Stock P/E 11.1
- Book Value ₹ 59.1
- Dividend Yield 0.00 %
- ROCE 18.4 %
- ROE 16.8 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 86.8% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.2%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 129 days to 258 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 30 | 59 | 62 | 83 | 104 | 112 | |
| 29 | 53 | 54 | 67 | 88 | 94 | |
| Operating Profit | 1 | 6 | 8 | 16 | 16 | 18 |
| OPM % | 5% | 11% | 13% | 19% | 15% | 16% |
| 0 | 0 | 0 | 0 | 4 | 3 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 6 | 7 | 14 | 19 | 18 |
| Tax % | 18% | 29% | 28% | 30% | 27% | 17% |
| 1 | 4 | 5 | 10 | 14 | 15 | |
| EPS in Rs | 8.45 | 8.28 | 9.17 | |||
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 22% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 87% |
| 3 Years: | 44% |
| TTM: | 11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 22% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 23% |
| Last Year: | 17% |
Balance Sheet
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 12 | 16 | 16 |
| Reserves | 5 | 9 | 14 | 17 | 65 | 80 |
| 3 | 3 | 4 | 5 | 30 | 8 | |
| 9 | 22 | 28 | 27 | 10 | 6 | |
| Total Liabilities | 18 | 35 | 47 | 61 | 122 | 111 |
| 6 | 7 | 10 | 10 | 12 | 15 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 7 | 52 | 16 |
| 12 | 27 | 37 | 44 | 58 | 79 | |
| Total Assets | 18 | 35 | 47 | 61 | 122 | 111 |
Cash Flows
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 1 | 3 | 4 | 3 | -23 | -11 | |
| -1 | -2 | -4 | -5 | -44 | 35 | |
| 0 | -0 | 0 | 2 | 67 | -24 | |
| Net Cash Flow | -0 | 1 | 0 | 0 | -0 | -0 |
| Free Cash Flow | -0 | 2 | 1 | 2 | -27 | -16 |
| CFO/OP | 103% | 57% | 72% | 46% | -120% | -34% |
Ratios
Figures in Rs. Crores
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 110 | 135 | 118 | 108 | 105 | 118 |
| Inventory Days | 12 | 9 | 97 | 113 | 99 | 163 |
| Days Payable | 119 | 140 | 215 | 144 | 26 | 24 |
| Cash Conversion Cycle | 3 | 4 | 1 | 77 | 178 | 258 |
| Working Capital Days | 9 | 14 | 27 | 58 | 72 | 258 |
| ROCE % | 55% | 47% | 57% | 27% | 18% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Capacity Utilization - Liquid Syrup % |
|
||
| Capacity Utilization - ORS Powder % |
|||
| Capacity Utilization - Tablets % |
|||
| Installed Capacity - Dry Syrup Kgs |
|||
| Installed Capacity - Liquid Syrup Lakh Liters |
|||
| Installed Capacity - ORS Powder Tons |
|||
| Installed Capacity - Tablets Crores |
|||
| Active Products Number |
|||
| Capacity Utilization - Dry Syrup % |
|||
| Presence in Indian States Number |
|||
| Production Volume - Syrup Millions |
|||
| Production Volume - Tablets Millions |
|||
| Total Licensed Formulations/Products Number |
|||
| Order Book (Myanmar) INR Crores |
|||
Extracted by Screener AI
Documents
Announcements
-
Disclosure under SEBI Takeover Regulations
2 June 2026 - Promoters disclosed no encumbrance on Quest Laboratories shares during FY2025-26.
-
Structural Digital Database
30 May 2026 - Quest Laboratories filed SDD compliance certificate for year ended 31 March 2026.
-
Outcome of Board Meeting
29 May 2026 - Board approved FY26 audited results; auditors appointed; 0.107-hectare Indore land bought for ₹321.20 lakh expansion.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
13 April 2026 - Regulation 74(5) certificate for quarter ended March 31, 2026; no rematerialisation requests received.
-
Trading Window
30 March 2026 - Trading window closed Apr 1, 2026 until 48 hours after results for quarter/year ended March 31, 2026.
Business Overview:[1][2]
a) QLL specializes in manufacturing a wide range of pharmaceutical formulations, including antibiotics, antimalarials, anti-inflammatories, respiratory medications,
diabetes treatments, and more.
b) Company also produces a wide range of ethical, generic, and over-the-counter (OTC) drugs in various forms, including tablets, liquids, oral powders, ORS, ointments, and external liquids.
c) Quest offers facilities for institutional supplies, domestic ethical products, PCD, Contract manufacturing, and export, with
a focus on a wide range of specialized formulations and molecules
d) The company has 800+ Licensed Formulations, 272+ Active Products, 25cr.+Order Book from Myanmar